StemRIM
JPX: 4599.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Masatsune Okajima
- Employees
- 44
- Headquarters
- Ibaraki, Japan
- IPO year
- 2019
- Market cap
- ¥18.8B
- Website
- https://www.stemrim.com
Loading 4599…
Loading profile data…Frequently asked questions about 4599
What does StemRIM (4599.T) do?
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy;...
Where does 4599.T trade?
StemRIM (4599.T) trades on the Tokyo Stock Exchange.
What sector is 4599.T in?
StemRIM (4599.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of StemRIM?
Masatsune Okajima is the chief executive officer of StemRIM (4599.T).
Where is StemRIM headquartered?
StemRIM is headquartered in Japan.
Does 4599.T pay a dividend?
StemRIM (4599.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4599.T go public?
StemRIM (4599.T) completed its initial public offering in 2019.